ConductScience.org, home

Paper16005263

Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.

Franco LM and 11 others. Mol Ther, 2005. Cited by 164 papers, by iCite.

Cite this record

ConductScience Library. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Papers, record 16005263. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16005263

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.
PubMed
Journal
Mol Ther
PubMed
Year
2005
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
164
iCite
Relative citation ratio, by iCite
3.6
iCite
Revised in PubMed
2012-11-15
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Franco LMLuis M
2Sun BBaodong
3Yang XXiaoyi
4Bird AAndrew
5Zhang HHaoyue
6Schneider AAyn
7Brown TTalmage
8Young SPSarah P
9Clay TMTimothy M
10Amalfitano AAndrea
11Chen YTY T
12Koeberl DDDwight D

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Creatine Kinase, MM FormMajor topic
Genetic VectorsMajor topic
Glycogen Storage Disease Type IIMajor topic
LiverMajor topic
alpha-GlucosidasesMajor topic
Animals
Antibody Formation
Creatine Kinase
DNA, Viral
Dependovirus
Enhancer Elements, Genetic
Gene Transfer Techniques
Genetic Therapy
Glycogen
Humans
Mice
Mice, Knockout
Muscle, Skeletal
Plasmids
Promoter Regions, Genetic

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R01-DK 52925NIDDK NIH HHSUnited StatesR01DK052925PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Cited by117

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 164 citations.

PMIDTitleJournalYearIn PapersSource
42442016Neonatal gene therapy with AAV2/8-LSPhGAA improves hypertrophic cardiomyopathy in the Gaac.1826dupA knock-in murine model.Mol Genet Metab2026https://conductscience.org/library/papers/42442016PubMed
41491260Assessment of Immune Responses Against AAV Encoded Transgene Products.AAPS J2026https://conductscience.org/library/papers/41491260PubMed
41485391Novel promoters drive therapeutic transgene expression and evade transgene-specific immune responses in a mouse model of Pompe disease.Mol Genet Metab2026https://conductscience.org/library/papers/41485391PubMed
41442049New advances in treating late-onset Pompe Disease: A narrative review.Eur J Pediatr2025https://conductscience.org/library/papers/41442049PubMed
41223291Liver-directed AAV gene therapy in mice corrects glycogen storage disease type IX γ2.Sci Adv2025https://conductscience.org/library/papers/41223291PubMed
41167625Enhancing AAV9-UFμDys1 Gene Therapy Efficacy Through Immunosuppression in Mice with Pre-Existing Immunity and Enabling Redosing Strategies for Duchenne Muscular Dystrophy.Hum Gene Ther2026https://conductscience.org/library/papers/41167625PubMed
41059362Long-Term Correction of Murine Glycogen Storage Disease Type III by AAV-Mediated Gene Therapy Using an Immunotolerizing Dual Promoter to Express Bacterial Pullulanase.Adv Cell Gene Ther2025https://conductscience.org/library/papers/41059362PubMed
40927766A myotropic AAV vector combined with skeletal muscle cis-regulatory elements improve glycogen clearance in mouse models of Pompe disease.Mol Ther Methods Clin Dev2025https://conductscience.org/library/papers/40927766PubMed
40183436Management of Pompe disease alongside and beyond ERT: a narrative review.Acta Myol2025https://conductscience.org/library/papers/40183436PubMed
39838066Incomplete elimination of viral genomes is associated with chronic inflammation in nonhuman primate livers after AAV-mediated gene transfer.Gene Ther2025https://conductscience.org/library/papers/39838066PubMed
39687734Preclinical efficacy and safety of adeno-associated virus 5 alpha-galactosidase: A gene therapy for Fabry disease.Mol Ther Methods Clin Dev2024https://conductscience.org/library/papers/39687734PubMed
39277505Neurological glycogen storage diseases and emerging therapeutics.Neurotherapeutics2024https://conductscience.org/library/papers/39277505PubMed
39134822Advances in Pompe Disease Treatment: From Enzyme Replacement to Gene Therapy.Mol Diagn Ther2024https://conductscience.org/library/papers/39134822PubMed
38753465Synergism of dual AAV gene therapy and rapamycin rescues GSDIII phenotype in muscle and liver.JCI Insight2024https://conductscience.org/library/papers/38753465PubMed
38664313Advances in Immune Tolerance Induction in Enzyme Replacement Therapy.Paediatr Drugs2024https://conductscience.org/library/papers/38664313PubMed
38138129AAV Immunotoxicity: Implications in Anti-HBV Gene Therapy.Microorganisms2023https://conductscience.org/library/papers/38138129PubMed
37759679A Comprehensive Update on Late-Onset Pompe Disease.Biomolecules2023https://conductscience.org/library/papers/37759679PubMed
37701327Screening data from 19 patients with late-onset Pompe disease for a phase I clinical trial of AAV8 vector-mediated gene therapy.JIMD Rep2023https://conductscience.org/library/papers/37701327PubMed
37463048AAV-mediated delivery of secreted acid α-glucosidase with enhanced uptake corrects neuromuscular pathology in Pompe mice.JCI Insight2023https://conductscience.org/library/papers/37463048PubMed
37421310Gene therapy for glycogen storage diseases.J Inherit Metab Dis2024https://conductscience.org/library/papers/37421310PubMed

See all 117 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
GAA2548PubTator's text mininghttps://conductscience.org/library/genes/2548

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/16005263

GET https://conductscience.org/api/papers/v1/16005263/cited_by?page=2